CRISPR Market to Worth $7.1 billion by 2028

Comments · 462 Views

The global CRISPR market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028.

According to the new market research report "CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028"

The globalCRISPR marketin terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028.

Request Sample Pages:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194978883

DRIVER: Growing Investment and Funding from the Government for CRISPR Technology
In recent years, there has been a notable increase in investment and funding from governments worldwide specifically directed towards CRISPR technology. This has created a conducive environment for research and development in the field, enabling breakthrough discoveries and propelling the market forward. For instance, in February 2023, Indian biotechnology start-up CrisprBits has raised $250,000 in pre-seed funding from US-based VJ Group. The funding will be used to develop products, expand the team and invest in research and development. CrisprBits plans to develop CRISPR-based diagnostics to detect pathogens and antimicrobial resistance genes.

Prominent companies in the market include well established, financially stable manufacturers of CRISPR products. These companies have been operating in the market for several years and possess diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US).

Report Objectives

  • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing the market growth
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically analyze the market structure and profile the key players of the market and comprehensively analyze their core competencies
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East Africa)
  • To track and analyze competitive developments such as product launches, acquisitions, partnerships, agreements, and collaborations in the Real World Evidence Solutions during the forecast period

Explore the Full Report with Charts, Table of Contents, and List of Figures:https://www.marketsandmarkets.com/Market-Reports/crispr-technology-market-134401204.html

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:

Company information

Detailed analysis and profiling of additional market players (up to 20)

About MarketsandMarkets:

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the GIVE Growth principle, we work with several Forbes Global 2000 B2B companies -helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, and facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn, and Facebook.

Contact:

Mr. Aashish Mehra

MarketsandMarkets INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +18886006441

Email:sales@marketsandmarkets.com

Comments